Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced it will host a conference call and webcast today at 6:00 p.m. Eastern Time to discuss the positive top-line results of its Phase 3 clinical trial of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Individuals interested in participating in the call should dial (888) 215-6825 (U.S. and Canada) or (913) 312-0844 (international) using conference ID number 4215125. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting September 13, 2010 at 9:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on September 27, 2010. To listen to the replay, dial (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) using conference ID number 4215125. An archived version of the event will be available on Ironwood’s website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC‐C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS‐C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.



CONTACT:

Ironwood Pharmaceuticals, Inc.
Susan Brady, 617-621-8304
Corporate Communications
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.